2022年10月1日 · Since the newer XPO1 inhibitor eltanexor (elta) is given 5 days/week in early-phase clinical studies, we compared the antileukemic effects of intermittent (2d/w) and …

In this study, we evaluated whether inhibition of SIK3 with the tool compound YKL-05-099 can suppress MEF2C function and attenuate disease progression in animal models of AML. …

XPO1 inhibition by selinexor (seli) leads to NPM1c nuclear relocalization, loss of HOX expression, and terminal differentiation. However, 2 days/week seli did not result in evident benefit for …

2022年10月1日 · Poster: AML-099 Prolonged XPO1 Inhibition Is Essential for Optimal Anti-Leukemic Activity in NPM1-Mutated AML October 2022 Clinical Lymphoma, Myeloma and …

2019年11月13日 · Our previous CRISPR screens in AML cell lines identified Salt-Inducible Kinase 3 (SIK3) as an essential gene for a subset of AML cells with high expression of the oncogenic …

2022年10月1日 · XPO1 inhibition by selinexor (seli) leads to NPM1c nuclear relocalization, loss of HOX expression, and terminal differentiation. However, 2 days/week seli did not result in …

2020年1月2日 · In this study, we evaluated whether inhibition of SIK3 with the tool compound YKL-05-099 can suppress MEF2C function and attenuate disease progression in animal …

AML-099 Prolonged XPO1 Inhibition Is Essential for Optimal Anti-Leukemic Activity in NPM1-Mutated AML

Context: RARA-positive AML is a novel, genomically defi ned subset with an actionable target for treatment with tamibarotene, an oral and selective RAR agonist (McKeown 2017). In a …

ykl-05-099是一种化学合成的sik抑制剂，主要抑制sik1和 中心点： AML细胞在体内外对盐诱导的激酶3的遗传或化学抑制均具有独特的敏感性。